Phenotypes Associated with This Genotype

Genotype
MGI:3703333

• Allelic Composition: Tg(Tek-Procr)1Cte/0
• Genetic Background: B6.FVB-Tg(Tek-Procr)1Cte

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal platelet physiology ( J:119637 )

• after treatment with high dose of factor Xa/PCPS, platelet consumption is significantly decreased in males compared to wild-type

homeostasis/metabolism

abnormal blood coagulation ( J:119637 )

abnormal platelet physiology ( J:119637 )

• after treatment with high dose of factor Xa/PCPS, platelet consumption is significantly decreased in males compared to wild-type

abnormal enzyme/coenzyme level ( J:119637 )

• after treatment with high dose of factor Xa/PCPS, thrombin generation is decreased in males compared to wild-type

• generation of thrombin antithrombin (TAT) complex is ~4 fold higher in wild-type than in male transgenic mice after treatment

abnormal acute phase protein level ( J:119637 )

• after treatment with high dose of factor Xa/PCPS, fibrinogen consumption is significantly decreased in males compared to wild-type

• fibrinogen levels 18 hours after LPS treatment are slightly higher in transgenic mice than in wild-type littermates

immune system

abnormal immune system physiology ( J:119637 )

• mice show significantly higher levels of circulating antigen presenting cells (APC) in response to LPS

abnormal acute phase protein level ( J:119637 )

• after treatment with high dose of factor Xa/PCPS, fibrinogen consumption is significantly decreased in males compared to wild-type

• fibrinogen levels 18 hours after LPS treatment are slightly higher in transgenic mice than in wild-type littermates

abnormal inflammatory response ( J:119637 )

• transgenic mice are resistant to death induced by LPS doses that are lethal to control wild-type mice; more than 905 of controls die within 60 hour compared to less than 65% of transgenic mice